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Background: Differential diagnosis of severe progressive dementia includes a wide spectrum of inflammatory and
neurodegenerative diseases. Particularly challenging is the differentiation of potentially treatable autoimmune
encephalitis and Creutzfeldt-Jakob disease. Such a coincidence may indeed complicate the correct diagnosis and
influence subsequent treatment.
Case presentation: A 75-year-old woman was admitted due to rapid progressive cognitive impairment. Her
husband observed a temporal disorientation and confusion. The initial neurological examination and an extensive
neuropsychological evaluation showed significant impairments in almost all tested cognitive domains. All other
neurological functions including motor, sensory and coordinative function were intact. Initial diagnostics included
EEG, MRI and lumbar puncture with unspecific results. Complementary blood testing revealed a positive result for
antineural antibodies to Contactin-associated protein 2 (CASPR2) and the patient received treatment for CASPR2
autoimmune encephalitis. Further symptoms and results, including 14-3-3 proteins, led to suspected Creutzfeldt-Jakob
disease. The postmortem examination supported the diagnosis of a definitive Creutzfeldt-Jakob disease.
Conclusion: One could argue that global screening for antineural antibodies may lead to a false diagnosis triggering
intense and potentially dangerous procedures. We believe, however, that potentially treatable causes of dementia
should aggressively sought out and subsequently treated in an attempt to curtail the course of disease and ultimately
reduce the rate of mortality.
Keywords: CASPR2, VGKC, Creutzfeldt-Jakob disease, Encephalitis, Autoimmune, Autoantibody, Thyroperoxidase
antibodiesBackground
Differential diagnosis of severe progressive dementia
includes a wide spectrum of inflammatory and neuro-
degenerative diseases. Particularly challenging is the differ-
entiation of potentially treatable autoimmune encephalitis
and Creutzfeldt-Jakob disease (CJD). Such a coincidence
may indeed complicate the correct diagnosis and influence
subsequent treatment. The diseases can mimic one an-
other to such an extent that one is led to believe that
the patient is suffering from CJD when he or she has in
fact a treatable autoimmune encephalitis [1-3] or vice
versa [2,4,5]. None of these VGKC complex antibodies* Correspondence: frederic.zuhorn@evkb.de
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unless otherwise stated.in CJD patients have been found to be directed to LG1
or CASPR2, yet.
We here report a recent case of Contactin-associated
protein 2-Antibody (CASPR2) production during ongoing
CJD, discuss the potential biological causes and the clini-
cal consequences.
Case presentation
A 75-year-old woman was admitted to our hospital due
to rapid progressive cognitive impairment. During the
previous year, the patient had shown mild cognitive im-
pairment due to moderate leukoariosis, thought to be
associated with arterial hypertension and hypercholester-
olemia. There was no positive family history of dementia
or dementia-like symptoms in the anamnesis. Ten days
before admission, her husband observed a temporal dis-
orientation and confusion, e.g. the patient could not recallLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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When admitted to our care the patient was conscious
but disorientated to place, time and person. The initial
neurological examination and an extensive neuropsy-
chological evaluation showed significant impairments
in almost all tested cognitive domains including attention,
concentration, memory, executive function and visual-
constructional ability. In addition, there was evidence of a
right-sided visual neglect, aphasia in terms of language
comprehension disorder and pronounced apraxic impair-
ments corresponding to dysfunctions of her left-sided pa-
rietal circuits. All other neurological functions including
motor, sensory and coordinative function were intact. An
initial electroencephalography showed unspecific ence-
phalopathy patterns. The MRI showed multiple micro-
angiopathic lesions: left-sided lesions in the thalamus,
parietooccipital, temporo mesial, thalamic, frontal and
parietal cortices, as well as right-sided lesions in the basal
ganglia. The brain-SPECT showed hypometabolism in
the frontoparietal and parietooccipital cortices, more
obvious on the left side, with normal nuclide accumula-
tion in motor and occipital cortex. The primary inves-
tigation of cerebrospinal fluid revealed a pleocytosis of
7 Leukocytes/μl [<5 Leukocytes/μl] with a Total Pro-
tein of 701 mg/l [<450 mg/l] and 2,31 mmol/l Lactate
[1,2-2,1 mmol/l]. Simultaneously, thyroperoxidase anti-
bodies (serum titre 1606 IU/ml [<60 IU/ml]) were de-
tected. It was initially concluded based on these results
that the patient was suffering from autoimmune en-
cephalitis, believed to be caused by autoimmune thy-
roiditis. High dosage intravenous methylprednisolone
therapy was initiated [6]. Despite treatment however,
the patient continued to exhibit cognitive and neuro-
psychological symptoms and presented the first tonic-
clonic seizure, leading to the initiation of LevetiracetamFigure 1 MRI formation of symmetrical hyperintensities in the putam
and FLAIR images.therapy. The ongoing diagnostic workup included a broad
search for potential autoimmune diseases. Serum and
CSF were tested for antibodies to the following antigens:
CASPR2, LGI1, NMDAR, GAD65, GAD67, GABABR,
AMPAR1/2, GlyR and onconeural antigens, whereby
CASPR2-antibodies were detected (serum titre 1:2000, see
Figure 1A; no antibody studies in CSF done). This result
was interpreted as support for the hypothesis of ongoing
autoimmune encephalitis. Treatment was now escalated
to eight tryptophan immunoadsorptions processing two
liters plasma per session. Although immunoadsorption ef-
fectively reduced the titre of CASPR2-antibodies (serum
titre 1:32), the patient’s cognitive and general neurological
condition worsened. A positron emission tomography was
now added to disclose malignancies. Apart from cystic
structures in kidneys and liver, no underlying oncological
disease was detected. Four weeks after the first MRI, fol-
low up imaging now revealed new hyperintensities in the
basal ganglia and both dorsal thalami [Figure 2 right]. Fur-
thermore, the EEG now presented a generalized periodic
pattern with triphasic waves. Continuous CSF studies now
showed normalization of Leukocytes (1/μl) and Total
Protein (292 mg/l), but increased Tau and 14-3-3 proteins
leading to the suspicion of a possible Creutzfeldt-Jakob
disease [7,8]. The patient continued to detoriate over the
following month after discharge, dying approximately
one year after the onset of symptoms. The postmortem
examination showed signs of spongiform encephalopa-
thy [Figure 3], supporting our diagnosis of a definitive
Creutzfeldt-Jakob disease [7,8].
Discussion
A rapidly progressive dementia with symptoms such as
disorientation, apraxia, aphasia, extrapyramidal dysfunc-
tion, and psychiatric symptoms caused by CJD may mimicen and caudate head within two months seen on T2-weighted
Figure 2 Cell based assays for demonstration of CASPR2 antibodies (Euroimmun, Lübeck, Germany). (A) Serum of patient diluted 1:15
incubated with HEK cells transfected with CASPR2; the antibodies are visualized by a Alexa 594 anti-human-IgG antibody; mild counterstaining
with Hoechst 33342. (B) Serum of a patient with classical limbic encephalitis and CASPR2 antibodies, technical details as in A. (C) Serum of patient
incubated with control cells not expressing CASPR2 (negative result), technical details as in A. These images demonstrate that the patient’s serum
does not bind non-specifically to the CASPR2 expressing HEK cells in A.
Zuhorn et al. BMC Neurology 2014, 14:227 Page 3 of 4
http://www.biomedcentral.com/1471-2377/14/227treatable types of autoimmune encephalitis. As shown
in the present case, thyroperoxidase- and CASPR2-
antibodies known to be associated with cognitive and
neuropsychological symptoms [9], can accompany the
devastating spongiform encephalopathy.
Our findings expand upon prior reports in which VGKC
complex antibodies were shown to be associated with
CJD. In previous studies, the patient had not been tested
for CASPR2 or LG1 [4] and the actual antigen could not
be identified. In addition, a recently published study [2]
demonstrated neuronal surface antigens in patients’ CSF
with rapid neurological deterioration. Patients in this
study suffered from different non-specific cognitive defi-
cits with variable degrees of memory loss and confusion.
Interestingly, none of the patients in this series with de-
finite CJD displayed antibodies against neuronal surface
antigens. Those few patients (1,7%) in whom neuronal
surface antigens were detected did not fulfill the diagnosticFigure 3 Frontal cortex (lower side towards pia mater; upper side tow
spongiosis and the diffuse synaptic PrP deposits. Brains were fixed in 4% fo
cut into 3 μm thick serial sections, mounted on glass slides and processed
Visualization of primary antibody was achieved using the diaminobenzidine
stainer (Ventana/Roche).criteria for probable or possible CJD. This is in contrast
to our finding, in which CASPR2-antibodies [Figure 1]
in serum were clearly associated with a positive test
for 14-3-3 protein and later on confirmed definite spo-
radic CJD by postmortem neuropathological analysis.
It should be noted that the first positive finding of
CASPR2-anibodies has been validated by a second test
for CASPR2-antibodies, in which the serum titre, paral-
lel to the decreasing CSF cell count, was significantly
lower as a result of immunoadsorption treatment.
Another case series reported about a 68-year-old pa-
tient with sporadic CJD tested positive for serum anti-
bodies to VGKC and GlyR antibodies but negative for
CASPR2 and LG1 antibodies [5].
Conclusion
The biological cause of this molecular mimicry is cur-
rently unknown and deserves further investigation. Oneards white matter), PrP; Scale bar 100 um. Note the confluent
rmalin and paraffin-embedded tissue samples of frontal cortex were
for immunhistochemical staining using specific antibodies to PrP.
streptavidin-biotin horseradish peroxidase method on an automated
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may have triggered an immunological reaction in periph-
eral lymph nodes causing antibody production against cer-
tain neuronal structures such as elements of voltage gated
potassium channels.
With the diagnosis still unconfirmed, we chose to initi-
ate therapy for the potentially treatable differential diagno-
sis. One could argue that global screening for antineural
antibodies led us to a false diagnosis triggering intense
and potentially dangerous procedures. We believe, how-
ever, that potentially treatable causes of dementia should
be aggressively sought out and subsequently treated to
avoid poor outcome. In fact, encephalitic syndromes are
treatable conditions that may mimic CJD [1,3].
The development of a CJD case into a progressive and
untreatable encephalopathy, as presented here, is cer-
tainly very rare. Nevertheless, such unique cases are im-
portant as they present new opportunities to study the
complex role of the immune system in the CNS.
Consent
Written informed consent was obtained from the legal
guardian of the patient for publication of this Case report
and any accompanying images. A copy of the written con-
sent is available for review by the Editor of this journal.
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